If you’re building a pharma brand in India, chances are your first product isn’t a tablet — it’s a syrup or a suspension. Liquid orals remain the highest-volume, most repeat-purchased category in Indian pharma marketing, from paediatric antibiotic suspensions to cough syrups to daily-use tonics. But finding the right third-party manufacturer for this category means understanding a few things that don’t show up in a generic “contract manufacturing” conversation: pack-size-driven pricing, MOQ logic, and the process steps that are unique to liquids.
This guide breaks down exactly what to expect — and what to ask — when sourcing a syrup or suspension manufacturing partner.
New to third-party manufacturing?
Start with our Complete Guide to Third-Party Pharma Manufacturing for the regulatory and business fundamentals before diving into product-specific detail here.
Why Syrups & Suspensions Dominate the Liquid Oral Market
Liquid orals sit at the intersection of high repeat-purchase behaviour and relatively approachable manufacturing economics compared to sterile or complex dosage forms. A few structural reasons this category performs so well for pharma marketing companies:
- Paediatric dependency — children’s formulations are almost exclusively liquid, and paediatric prescriptions repeat frequently across a household.
- Brand stickiness — once a physician trusts a particular suspension’s taste-masking and tolerability, they tend to keep prescribing it.
- Lower entry barrier than injectables — while still WHO-GMP regulated, liquid orals don’t require sterile fill-finish infrastructure, keeping manufacturing costs more accessible for new brands.
Understanding Pricing: The Four Levers
Unlike a flat “per bottle” quote you might expect, syrup and suspension pricing is built from four separate variables. Understanding each one lets you negotiate intelligently instead of just comparing headline numbers across manufacturers.
| Pricing Lever | What It Affects | Why It Matters |
|---|---|---|
| API / Active Cost | Base cost of the drug substance | Fluctuates with global API pricing; largest single line item for high-dose actives |
| Pack Size | Per-unit fill volume (30ml–200ml) | Larger packs cost more per bottle but less per ml — affects your retail price point |
| Packaging Complexity | Bottle type, cap, measuring device | Custom moulds and premium closures raise both cost and MOQ |
| Batch Size | Total units per production run | Larger batches lower per-unit conversion cost through economies of scale |
MOQ by Pack Size: What to Expect
Minimum order quantities for syrups and suspensions are driven primarily by batch economics — the manufacturer needs enough volume per run to justify tank setup, in-process testing, and line changeover time.
| Pack Size | Typical MOQ (Validated Formulation) | Typical MOQ (New Formulation) |
|---|---|---|
| 60ml | ~5,000–10,000 bottles | 10,000+ bottles (post-stability approval) |
| 100ml | ~5,000–7,500 bottles | 7,500–10,000 bottles |
| 200ml | ~3,000–5,000 bottles | 5,000–7,500 bottles |
Figures are indicative ranges and vary by manufacturer, active ingredient, and packaging source — always confirm exact MOQ during your product feasibility discussion.
The Process: From Brief to Dispatch
Liquid oral manufacturing has a few process steps that solid dosage forms (tablets, capsules) don’t require. Here’s what a realistic development-to-dispatch flow looks like:
- Formulation Brief (Week 1) — Active, strength, flavour profile, target pack size, reference product (if any)
- Prototype & Taste Masking (Week 2–4) — Especially critical for antibiotic suspensions and paediatric products; organoleptic panel testing confirms palatability
- Viscosity & Suspension Stability (Week 3–5) — For suspensions specifically: confirming the suspending agent prevents sedimentation and passes “shake well” redispersibility testing
- Preservative Efficacy Testing (PET) (Week 4–6) — Multi-dose liquid products must demonstrate the preservative system controls microbial growth throughout in-use shelf life
- Stability Studies (Month 2+) — Accelerated (40°C/75% RH, 6 months) and real-time (25–30°C, full shelf life) per ICH Q1A
- Pilot Batch & Scale-Up (Month 3–4)
- Regulatory Filing & License (Month 3–5)
- Commercial Batch 1 (Month 4–6, or 30–45 working days for an already-validated product)
View manufacturing details for Levosalbutamol, Ambroxol & Guaiphenesin Syrup
Packaging Options You Should Know About
Packaging isn’t an afterthought for liquid orals — it directly affects both cost and shelf presence:
- Bottle material: Amber PET (light-protective, standard for most syrups) vs. clear PET (used for cosmetic-clarity products)
- Dosing devices: Measuring cup (standard adult syrups), dosing spoon, or oral dispenser/dropper (paediatric suspensions requiring precise small-volume dosing)
- Cap type: Child-resistant closures are increasingly requested for paediatric antibiotic suspensions
- Secondary packaging: Mono-carton with insert leaflet vs. shrink-wrapped bottle-only
Quality Control Specific to Liquid Orals
Liquid orals carry meaningfully different QC requirements than tablets — particularly around microbial contamination risk and dose uniformity for suspensions. If you haven’t already, review our detailed breakdown of the WHO-GMP quality control process, which covers HPLC assay testing, batch release protocols, and stability testing in depth.
How Saar Biotech Delivers on Syrups & Suspensions
Liquid orals are the core of what we do. Operating 4 specialized manufacturing units in Baddi, we’ve developed and stability-tested over 240 formulations — a large share of them syrups and suspensions across paediatric, general, and specialty categories — for 2100+ partner brands across India.
What this means practically for a new brand owner:
- Faster launches on our existing approved formulation list (30–45 working days)
- Full taste-masking and PET validation built into our standard development process, not billed as an extra
- Flexible MOQs for first-time partners and PCD franchise owners
Conclusion
Syrup and suspension manufacturing rewards brand owners who understand the specifics — pack-size-driven MOQ, the four pricing levers, and the extra process steps (taste masking, PET, viscosity stability) that liquids require beyond standard tablet manufacturing. Choosing a manufacturer who can walk you through each of these transparently, rather than just quoting a flat per-bottle rate, is the clearest signal of a reliable long-term partner.
Ready to discuss your syrup or suspension formulation?